Brigatinib becomes potential new first-line option for ALK-positive non-small lung cancer
Results of a 275-patient, multi-national phase III clinical trial known as ALTA-1L published today in the New England Journal of Medicine and presented concurrently in the press program at the International Association for ...
Sep 25, 2018
0
5